Angle Plc Stock Price, News & Analysis

ANGLE plc (OTCQX: ANPCY) will release its interim results for the six months ended June 30, 2022, on September 29, 2022. An analyst meeting is scheduled for 11:00 am BST at FTI Consulting’s London office and will be available via a live webcast. The Parsortix® system, which captures circulating tumor cells from blood, is FDA cleared for metastatic breast cancer, marking a significant achievement in liquid biopsy technology. ANGLE's technologies have shown promising results in clinical studies, enhancing diagnostic accuracy and potential in cancer treatment.

ANGLE plc (OTCQX:ANPCY) has announced the issuance of 33,332 new ordinary shares following the exercise of employee options. These shares will rank pari passu with existing shares and are expected to commence trading on AIM on July 13, 2022. Post-admission, the total number of ordinary shares will reach 235,328,048, thereby increasing total voting rights. ANGLE's Parsortix system, FDA cleared for use in metastatic breast cancer, continues to gain traction in the liquid biopsy market, underlining the company's commitment to cancer diagnostics and monitoring.

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announced that all resolutions were passed at their Annual General Meeting on June 29, 2022. The company specializes in liquid biopsy technology, particularly its Parsortix system, which has received FDA clearance for harvesting circulating tumor cells from blood in metastatic breast cancer patients. ANGLE is developing additional clinical applications, including a pelvic mass triage test showing 95.1% accuracy. Its technologies are supported by collaborations with major corporations and cancer centers to enhance clinical utility.

ANGLE plc has announced significant research results from ETH Zurich, revealing that breast cancer metastasis accelerates during sleep. The study found that circulating tumor cells (CTCs) and their clusters are more prevalent and aggressive at rest. This discovery suggests a potential for time-controlled cancer treatments that could optimize patient care. The findings underscore the role of circadian rhythms and associated hormones in cancer cell behavior, providing new avenues for drug development and improving treatment strategies for breast cancer.

ANGLE plc (OTCQX:ANPCY) has issued 144,999 new ordinary shares following the exercise of employee options. These shares will rank equally with existing shares. The admission for trading is expected to commence on June 28, 2022, increasing the total shares in issue to 235,294,716. This move reflects the company's ongoing efforts to support its liquid biopsy solutions, particularly the Parsortix system, which is FDA cleared for metastatic breast cancer. The press release highlights ANGLE's commitment to innovation and growth in cancer diagnostics.

ANGLE plc has secured an additional contract valued up to US$1.2 million with a large pharmaceutical customer for a Phase Ib dose-escalation study involving its Parsortix liquid biopsy system. This study will focus on the longitudinal monitoring of patients with unresectable solid tumors during drug intervention. The contract signifies ongoing interest in ANGLE's services following FDA clearance of Parsortix, with expectations for future studies to expand further into Phase II and III.

ANGLE plc announces significant findings from a study conducted by Edith Cowan University, demonstrating the capability of the Parsortix system to predict immunotherapy responses in small cell lung cancer (SCLC). The study isolated circulating tumor cells (CTCs) from blood samples, identifying PD-L1 expression. In testing 20 samples from 18 patients, CTCs were found in 50%, with 40% showing PD-L1 positivity. This innovative approach provides an alternative to traditional tissue biopsies, potentially enhancing patient selection for immunotherapy, amidst low response rates of 13% to 50% for existing treatments.

ANGLE plc reports groundbreaking findings from researchers at King's College London regarding the role of invasive cellular protrusions in prostate cancer. Their Parsortix system successfully isolated circulating tumor cells (CTCs) in 94% of prostate cancer patients, revealing potential therapeutic targets in the metastatic process. The study highlights how CTCs may form invadopodia for easier bloodstream entry, emphasizing the need for targeted treatments as the survival rate drops significantly once cancer metastasizes. These insights are crucial for developing new therapies aimed at improving patient outcomes.

ANGLE plc has formed a partnership with Solaris Health Holdings and MidLantic Urology to conduct clinical studies on prostate cancer using the Parsortix system. This collaboration aims to evaluate a liquid biopsy as a safer pre-screening tool before invasive biopsies, addressing a significant need in prostate cancer diagnostics. The studies will enroll 100 men with elevated PSA levels, with results expected in 2023. If successful, the Parsortix system could offer a non-invasive option for patients and potentially lead to regulatory submissions, tapping into a vast market with over 11 million annual PSA tests in the U.S.